Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Expert Rev Vaccines. 2021 Jun 9;20(7):827–837. doi: 10.1080/14760584.2021.1935248

Figure 2:

Figure 2:

Sequencing-based identification of cancer neoantigens. Tumor and patient genomes are sequenced and variant calling is performed between the two sequences. Identified mutations are processed by neoantigen prediction algorithms based on known rules of HLA binding and antigen processing to predict neoantigen candidates.